Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026837 (muscle rigidity)
 1,077 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The use of monofilament nonabsorbable suture materials is not common in Dentistry. Although it is known that multifilament suture materials induce greater cellular reaction, most Dentists prefer to use cotton and silk. Rigidity and package memory are disadvantages of monofilament nonabsorbable suture materials. A new material, Polybutester (Novafil), has been used successfully in Medicine but its use is not common in Dentistry. Seventy male and female Wistar rats were used to study the clinical response of skin and abdominal wall muscle to the use of Novafil and nylon sutures. Under general anesthesia, standard wounds were created in the dorsum and abdomen of the animals and sutured with either Novafil or nylon. The animals were sacrificed immediately, 12, 24, and 72 hours and at 4, 5 and 7 days to evaluate the clinical aspect of both wounds. Polybutester presented some advantages such as strength, lack of package memory, elasticity and flexibility which made suturing quicker and easier. Some subjects presented abdominal wound edema during the period and six animals developed infection of abdominal wounds within seven days. These initial findings show that Novafil is easy to handle and would be better tolerated in the mouth than nylon resulting in less discomfort for the patient. Novafil can be used safely on skin and mucosal wounds and, if necessary, it can be used in internal sutures because it irritates less than nylon.
 ...
PMID:Using Novafil: would it make suturing easier? 948 33

Pharmacotherapy of schizophrenia is associated with the stressful side effects. Muscle rigidity causes distress, discomfort and poor compliance. The aim of the study was to determine the relationship between plasma hormones (cortisol and prolactin/PRL) and muscle rigidity in female schizophrenic patients treated with olanzapine or fluphenazine. In a randomized, double-blind 22-weeks study, 12 patients were treated with olanzapine (5-20 mg/day) and 10 patients received fluphenazine (6-21 mg/day). Treatment with olanzapine moderately decreased, while treatment with fluphenazine significantly increased plasma cortisol levels and muscle rigidity. The marked and moderate increase in plasma PRL levels were found in patients treated with fluphenazine and olanzapine, respectively. The results suggested that olanzapine induced moderate neuroendocrine effects and a reduction in rigidity as compared to fluphenazine treatment.
 ...
PMID:The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. 1712 74

A 54-year-old Japanese woman was diagnosed with major depressive disorder and prescribed paroxetine 20 mg/day. In around May 2013, the patient experienced gastric discomfort, so metoclopramide was prescribed. Beginning on June 4, 2013, the patient was given metoclopramide, 10 mg intravenously, twice per week. On the seventh day after beginning metoclopramide, facial hot flushes, increased sweating, muscle rigidity, and galactorrhea were noted. Extrapyramidal symptoms (EPS) rapidly subsided in response to an intramuscular injection of biperiden. Blood biochemical tests revealed an elevated serum prolactin level of 44 ng/mL. After stopping metoclopramide, EPS disappeared. Serum prolactin level decreased to 15 ng/mL after 4 weeks. In our case, although no adverse reactions had previously occurred following the administration of metoclopramide, the patient developed EPS and hyperprolactinemia following the administration of this antiemetic in combination with paroxetine. Paroxetine and metoclopramide are mainly metabolized by CYP2D6, and they are inhibitors for CYP2D6. We report a case with EPS and hyperprolactinemia whose plasma paroxetine and metoclopramide level rapidly increased after the addition of metoclopramide. Our experience warrants the issuing of a precaution that adverse reactions may arise following the coadministration of metoclopramide and paroxetine even at their respective standard dose levels.
...
PMID:Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. 2762 38